Post-stroke angiogenesis facilitates neurovascular remodeling process and promotes neurological recovery. Proangiogenic effects of Salvianolic acids (Sals) have been reported in various ischemic disorders. However, the underlying mechanisms are still poorly understood. Previous studies of our laboratory have demonstrated that activating Janus kinase 2/ signal transducer and activator of transcription 3 (JAK2/ STAT3) signaling pathway is involved in the protection against cerebral ischemia/reperfusion injury. In this study, we investigated the impacts of Sals on angiogenesis and long-term neurological recovery after ischemic stroke as well as the potential mechanisms. Male mice subjected to permanent distal middle cerebral artery occlusion were administrated with Sals, 5-bromo-2 0 -deoxyuridine, and JAK2 inhibitor AG490 once daily from day 1 to day 14 after distal middle cerebral artery occlusion. Compared with the control group, Sals treatment significantly improved neurological recovery at day 14 and 28 after ischemic stroke. Sals enhanced post-stroke angiogenesis, pericytes and astrocytic endfeet covered ratio in the peri-infarct area. The JAK2/STAT3 signaling pathway was activated by Sals in the angiogenesis process, and inhibition of JAK2/STAT3 signaling blocked the effects of Sals on poststroke angiogenesis and neurological recovery as well as abolished the mediation of proangiogenic factors. In summary, these data suggest that Sals administration enhances cerebral angiogenesis and promotes neurological recovery after ischemic stroke, mediated by the activation of JAK2/STAT3 signaling pathway.
delivers (at least partly) the solution (Rigau et al. 2007; Reeson et al. 2015) . Emerging evidence has proved that astrocytes and pericytes are critically required for neurovascular remodeling during stroke recovery (Winkler et al. 2011; Hayakawa et al. 2012) . Salvia miltiorrhiza, a herbal traditional medicine, has been widely used for treating ischemic diseases, such as coronary artery diseases and cerebrovascular diseases (He et al. 2008; Wang et al. 2010; Wu et al. 2012) . Two major active constituents of Salvia miltiorrhiza, hydrophobic components and hydrophilic components, have been isolated, and Salvianolic acids (Sals) are the most abundant part of the hydrophilic components (Sun et al. 2005; Han et al. 2008) . It has been reported that Sals enhance angiogenic process in rats with myocardial infarction (Guo et al. 2014) and promote angiogenesis in vitro (Lay et al. 2003a,b) . However, the underlying mechanism mediating the impacts of Sals on post-stroke angiogenesis remains elusive.
Angiogenesis is tightly regulated by an orchestrated balance with proangiogenic and anti-angiogenic factors. Vascular endothelial growth factor (VEGF), a crucial stimulator for blood vessel formation, initiates formation of immature vessels, and angiopoietins (Angs) are involved in maturation, stabilization, and remodeling of the initially immature vasculature (Yancopoulos et al. 2000) . As a direct transcriptional activator of VEGF under hypoxia, signal transducer and activator of transcription 3 (STAT3) has recently been shown to promote post-stroke angiogenesis (Gertz et al. 2012; Hoffmann et al. 2015) . STAT3 is phosphorylated by phospho-Janus kinase 2 (pJAK2) and subsequently translocated into the cell nucleus, where it regulates the expression of target genes (Liu et al. 2014b; Quarta et al. 2014) . Our previous studies have also demonstrated that activation of JAK2/STAT3 signaling pathway results in the protection against cerebral ischemia/reperfusion injury (Liu et al. 2014b) . Accumulating evidence has shown that JAK2/STAT3 signaling pathway participates in angiogenesis through inducing VEGF production . Furthermore, blockage of STAT3 pathway is associated with the suppression of pancreatic tumor and renal cell carcinoma by inhibiting tumor angiogenesis (Boreddy et al. 2011; Li et al. 2013) . Thus, it is reasonable to propose that JAK2/ STAT3 signaling pathway may be involved in the Salsinduced angiogenesis after ischemic stroke. In this study, we tested whether treatment of ischemic stroke with Sals promoted angiogenesis and functional recovery through JAK2/STAT3 signaling pathway.
Materials and methods
Male C57BL/6 mice (RRID: IMSR_CRL:27, age 2-3 months, weight 25-30 g) were purchased from the Vital River Laboratory Animal Technology Co. Ltd, Beijing, China. All mice were allowed to acclimatize to the new surroundings for at least 3 days before experiments. During this period, all mice had free access to food and water under controlled conditions (12/12 h light/dark cycle with humidity of 60 AE 5%, 22 AE 3°C). All studies were approved by the local experimental ethics committee as well as the institutional animal care and use committee.
Experimental design and treatment
The experimental outline was shown in Fig. 1 . In the first set of studies, mice were randomly assigned to six groups. Section one: (i) distal middle cerebral artery occlusion (dMCAO) group: animals received dMCAO and equal volume of 0.9% NaCl; (ii) Sals (10 mg/ kg, i.p.) group: animals underwent dMCAO and were treated with a low dose of Sals (10 mg/kg); (iii) Sals (30 mg/kg, i.p.) group: animals underwent dMCAO and treated with a high dose of Sals (30 mg/kg). Section two: (i) dMCAO group; (ii) dMCAO + AG490 group: animals underwent dMCAO and treated with 5 mg/kg AG490; (iii) Sals (30 mg/kg, i.p.) + AG490 group. These animals were used for functional tests. They were killed at day 28 after dMCAO for hematoxylin and eosin (H&E) staining.
In the second set of studies, mice were randomly assigned to five groups: (i) Sham group: animals received sham operation and equal volume of 0.9% NaCl; (ii) dMCAO group; (iii) Sals (30 mg/kg, i.p.) group; (iv) dMCAO + AG490 group; (v) Sals (30 mg/kg, i.p.) + AG490 group. These animals were administrated with 5-bromo-2 0 -deoxyuridine (BrdU), intraperitoneally (i.p.) once daily from day 1 to day 14 after dMCAO. They were killed at three time points after dMCAO (day 7, 14, 28), used for immunohistochemical analysis and Evans blue studies. In the third set of studies, mice were randomly assigned to five groups: (i) Sham group; (ii) dMCAO group; (iii) Sals (30 mg/kg, i.p.) group; (iv) dMCAO + AG490 group; (v) Sals (30 mg/kg, i.p.) + AG490 group. These animals were killed at day 3, 7, and 14 after dMCAO, used for western blot, quantitative real-time PCR (rtqPCR) studies. In each study, mice were randomly assigned according to the randomization table. Drug treatment was performed deoxyuridine (BrdU), or AG490 were administrated intraperitoneally once daily from day 1 to day 14 after distal middle cerebral artery occlusion (dMCAO). The rotarod test and modified neurologic severity scores (mNSS) were performed at day 1, 7, 14, and 28 after dMCAO and mice were trained for 3 days before dMCAO for the rotarod test. Western blot and rt-qPCR were performed at day 3, 7, and 14. Immunostaining was performed at day 7, 14, and 28. Evans Blue extravasation was performed at day 7 and 14. The infarct volumes were measured at day 28.
in a blinded manner. The investigators involved in data analysis were blinded to sample identity.
Animal model of stroke
Detailed procedures of dMCAO have been described previously . Briefly, mice were anesthetized intraperitoneally with Avertin (400 mg/kg, T48402-25G; Sigma-Aldrich, St Louis, MO, USA) followed by permanent ligation of the right common carotid artery. A craniotomy with diameter 3 mm was drilled in temporal bone after the temporal muscle was removed laterally. Finally, the right middle cerebral artery (MCA) distal to the striatal branch was coagulated with a cauterizer (RWD LIFESCIENCE). Cerebral blood flow in the MCA area was monitored using a blood flow monitor (moor VMS-LDF; Moor Instruments Ltd., Devon, UK), and mice were excluded with a criterion of > 25% of basal flow after dMCAO. A total of 12 mice were excluded because of death or failing to meet the criteria. The animals' body temperature was maintained at 36-37.5°C during the experiments. In Shamoperated mice, the MCA was exposed but not occluded.
Drug administration
Sals (Low dose: 10 mg/kg; High dose: 30 mg/kg; Tianshili, Tianjin, China), AG490 (5 mg/kg in 45% dimethyl sulfoxide; HY-12000; MedChem Express, New Jersey, USA), and BrdU (50 mg/kg in 0.9% NaCl; B5002G; Sigma, St. Louis, MO, USA) were administrated intraperitoneally once daily for 14 continuous days from day 1 after stroke.
Behavioral tests
Behavioral tests were assessed by an investigator blinded to the experimental groups.
Rotarod test
The rotarod test was performed to evaluate the sensorimotor deficits. Mice (placed on a rotating rod with a speed accelerating from 4 to 40 rpm within 5 min) were allowed to practice for three times once daily for three consecutive days with a 15-minute break before dMCAO. Mice underwent three trials on the rotarod. The latency to fall from the rod of each mouse was recorded and the average duration of each mouse was calculated to evaluate the performance.
Modified neurologic severity scores
The modified neurologic severity scores (mNSS), ranging from 0 to 14 (normal to maximal deficit score 14), is a scale to evaluate the neurological function of motor, sensation, and balance (Li et al. 2000) . In this test, one score point is awarded for the incapability to accomplish the test or for the lack of a tested reflex. Thus, the higher scores indicate more severe neurological behavioral impairments.
Infarct volume analysis
Hematoxylin and eosin staining was performed to assess the infarct volumes. Detailed descriptions of the procedures are provided in the Online Resource S1.
Preparation of brain sections and immunohistochemistry
Mice were fixed by transcardial perfusion with 4% paraformaldehyde after perfusion with 0.01 M phosphate-buffered saline. The brains were immersed in 30% sucrose for 24 hours at 4°C, and sectioned at 30 lm with a cryostat. Two coronal sections including focus of infarct and cerebral cortex in the ipsilesional hemisphere were selected. Each slide contained two fields in the ischemic boundary zone of interest. Briefly, free-floating brain sections were incubated with blocking solution (10% donkey serum and 0.3% Triton X-100 in phosphate buffered saline) for 1 h at room temperature, followed by incubation with primary antibodies overnight at 4°C. The primary antibodies included rat anti-cluster of differentiation 31 (CD31) antibody (1 : 50; BD Biosciences, San Jose, CA, USA Cat# 550274, RRID: AB_393571), mouse anti-glial fibrillary acidic protein (GFAP) (1 : 500; Millipore, Darmstadt, Germany Cat# NE1015, RRID: AB_2043416), rabbit anti-NG2 (1 : 500; Millipore, Darmstadt, Germany Cat# AB5320C3, RRID: AB_11203295), goat anti-Ang-1 (1 : 500; Santa Cruz, Santa Cruz, CA, USA Cat# sc-6319, RRID: AB_633886), goat anti-Ang-2 (1 : 500; Santa Cruz, Cat# sc-7017, RRID: AB_2226218), rabbit anti-VEGF (1 : 500; Santa Cruz, Cat# sc-152, RRID: AB_2212984), mouse anti-neuronal nuclei (1 : 500; Chemicon; Temecula, CA, USA, Cat# MAB377, RRID: AB_2298772), rabbit anti-tyrosine kinase receptors 2 (1 : 500; Santa Cruz, Cat# sc-324, RRID: AB_631102), and rabbit anti-fetal liver kinase 1 (1 : 500; Santa Cruz, Cat# sc-504, RRID: AB_632600) antibodies. To detect BrdU incorporation, the sections were fixed again with 4% paraformaldehyde for 15 min, denatured with 2 N HCl at 37°C for 30 min, and then neutralized in 0.1 M boric acid (pH 8.5) for 10 min. The samples were incubated with mouse anti-BrdU (1 : 200; BD Biosciences, Cat# 555627, RRID:AB_395993) antibody. The sections were then incubated with proper secondary antibodies at 21-22°C for 2 h. Negative control sections were processed in the same manner without primary antibodies.
Immunofluorescence was visualized using a Laser Scanning Confocal Microscope (Olympus FV10-ASW, Tokyo, Japan). Z-stack slices with 2 lm intervals for CD31 were captured through a 209 objective. Microvessel density was analyzed using Image J software (National Institutes of Health, Bethesda, MD, USA). BrdU-, NG2-, and GFAPpositive vessels counting were performed manually with Image J by an investigator blinded to experimental condition.
Evans blue extravasation
Evans blue extravasation was measured to quantify vascular permeability. Detailed descriptions were provided in the Online Resource S2.
Western blot
Proteins were isolated from the cortex of the ischemic hemisphere using a total protein extraction kit from Applygen Technologies Inc., (Beijing, China) following the manufacturer's protocols. The total protein contents of the samples were determined by a bicinchoninic acid (BCA) Protein Assay reagent kit (Novagen, Madison, WI, USA). Equal amounts of proteins from different samples were loaded and separated by sodium dodecyl sulfate/ polyacrylamide gelelectrophoresis electrophoresis followed by transfer to polyvinylidene difluoride membranes, which were then incubated with blocking buffer (5% non-fat dry milk) at room temperature for 1 h and incubated with the primary antibodies overnight at 4°C. The primary antibodies included rabbit anti-JAK2; rabbit anti-STAT3 
Statistical analysis
Sample sizes were determined based on effect sizes observed in our previous study (Liu et al. 2014b; Cui et al. 2015) and our pilot studies. Sample size calculation and power analysis were performed using online tools (http://powerandsamplesize.com/) (power = 0.8, a = 0.05). The sample sizes needed were shown in Figure S1 . All data were expressed as mean AE SEM. Statistical analysis was performed by one-way ANOVA and followed by Student-NewmanKeuls test for intergroup comparisons. Comparisons between two groups were evaluated by the Student's t-test. Non-parametric analyses were performed with the Kruskal-Wallis test for mNSS. P < 0.05 was considered statistically significant.
Results
Sals improve neurological recovery after stroke without affecting chronic infarct volume At day 1, there was no significant difference between dMCAO and Sals groups in terms of functional outcomes. At day 14 and 28, the dMCAO mice treated with high-dose Sals (30 mg/kg) exhibited significantly longer duration on the rotarod and lower neurologic deficit scores, compared with those treated with low-dose Sals (10 mg/kg). Compared with the control group, low-dose Sals administration failed to induce remarkable functional improvement at any time points. Therefore, treatment of 30 mg/kg Sals was selected in the following experiments ( Fig. 2a and b) . The lesion volumes were comparable between Sals and dMCAO group at day 28 ( Fig. 2c) . Body weights of the mice were monitored after stroke, showing no significant difference after stroke among the three experimental groups (Fig. 2d) . These results indicated that Sals improved long-term neurological recovery after stroke without affecting the change in chronic lesion volume.
Sals enhance post-stroke angiogenesis
We first recorded natural development of post-stroke angiogenesis in the ipsilateral cortex from dMCAO group to set the baseline. As shown in Fig. 3(a) , microvessel density started increasing at day 7 and continued expanding during day 14-28. The regions of the immunostaining measurement were shown in Fig. 3(b) . Sals administration strikingly elevated microvessel density at later time points after stroke (day 14 and 28), though microvessel density was comparable between Sals group and dMCAO group at day 7 (Fig. 3c) . In addition, we detected infarct volumes stained by 2,3,5-triphenyltetrazolium chloride and observed the newly emerged blood vessels in the peri-infarct area on the brain surface stained with Evans Blue. The results demonstrated a remarkable formation of blood vessels around the ischemic core accompanied by reduced infarct area (Fig. 3d) .
To determine endothelial cells (ECs) proliferation, the number of BrdU + /CD31 + ECs located in blood vessels was quantified at day 14 (Fig. 4a) . Compared with the dMCAO group, the frequency of BrdU + ECs in the Sals group significantly increased at day 14 (Fig. 4b) . Newly formed vessel walls are permeable during the early stages of development, and become less leaky as vessel integrity increases. Therefore, we performed Evans blue extravasation to determine vascular permeability. In the dMCAO group, extravasation of Evans blue reached to the maximum level at day 7 and significantly decreased at the following time points, suggesting that new vessels formed at day 7 and integrity was restored at day 14 and 28 ( Fig. 4c) . Furthermore, at day 7, Sals-treated mice showed more extravasation than dMCAO group, whereas no significant difference was observed at day 14 compared with Sham and dMCAO groups, consistent with our immunofluorescence results ( Fig. 4d and e) .
Sals promote pericytes proliferation and coverage around microvessels Pericytes are critical for the regulation of vascular stabilization and remodeling. As shown in Fig. 5(a) and (b) , the pericyte processes extended to the vessels and the basement membrane of pericytes ensheathed along the long axis of capillaries, wrapping around ECs with cytoplasmic processes. At day 7, NG2 + pericytes were rarely detected around the microvessel endothelium in both dMCAO and Sals groups. However, at day 14 and 28, pericytes coverage in the Sals group was significantly elevated compared with the dMCAO group ( Fig. 5c and d) . In addition, BrdU + pericytes were found in the Sals group (Fig. 5e) , suggesting that the newly generated pericytes might contribute to new vessels stabilization in the peri-infarct area.
Sals promote astrocytic foot processes wrapping the blood vessels and astrocytes proliferation in the peri-infarct area At day 7, the ratio of GFAP + astrocytes coverage was comparable between Sals and dMCAO groups. As expected, at day 14 and 28, Sals-treated mice showed a significant increase in astrocytes covered ratio compared with the dMCAO group. Sals administration induced the aggregation of astrocytes that exhibited a stream-like structure pointing to the ischemic core, with elongated processes wrapping the blood vessels. In contrast, few astrocytic endfeet were found surrounding ECs in the contralateral hemisphere (Fig. 6a-c) . Moreover, GFAP + /BrdU + astrocytes were observed in the peri-infarct area, indicating potent mitotic potential of reactive astrocytes (Fig. 6d) .
The JAK2/STAT3 signaling pathway, activated by Sals in the angiogenesis process, may mediate VEGF, Ang-1, and Ang-2 expression Next, we ought to determine whether JAK2/STAT3 signaling pathway was involved in the proangiogenic outcomes induced by Sals. Western blot and rt-qPCR were performed to examine the expression and phosphorylation of JAK2 and STAT3. Mice were killed at day 3, 7, and 14. The protein levels of JAK2 and STAT3 did not show significant differences among the experimental groups. However, the phosphorylated levels of JAK2 and STAT3 (pJAK2 and pSTAT3) were significantly enhanced after Sals treatment at the three time points compared with the dMCAO group (Fig. 7a) . To assess the impacts of Sals on proangiogenic factors after stroke, the expression of VEGF, Ang-1, and Ang-2 was determined. The protein level of VEGF was significantly up-regulated in the Sals group at day 3, 7, and 14 in the ipsilateral cortex compared with the dMCAO group. However, the significant up-regulation of Ang-1 induced by Sals was only detected at late time points (day 7 and 14), showing a delay time frame compared to the induction of VEGF. Similar to the modulation of Ang-1, Ang-2 expression was significantly reduced by the Sals treatment at day 7 and 14, but not at day 3. (Fig. 7b) . In addition, no marked change was observed in the contralateral cortex among the three groups . In line with the results of western blot, rt-qPCR analysis showed that there was no difference in the expression of total JAK2 and STAT3. We also found that Sals mediated the expression of VEGF from day 3, maintaining up to at least day 14, whereas significant difference of Ang-1 and Ang-2 was shown from day 7 to 14 between Sals and dMCAO groups ( Fig. 7c and Figure S2d) .
Furthermore, the distribution of VEGF, Ang-1 and Ang-2 after Sals treatment was examined. Our results showed that the three factors were scarcely colocalized with CD31 + or GFAP + cells in the peri-infarct area. In contrast, they were expressed in NeuN + neurons (Fig. 7d) , suggesting that Sals may trigger the expression of VEGF, Ang-1, and Ang-2 mainly in neurons but not in ECs or astrocytes. We found colocalization of fetal liver kinase 1 and tyrosine kinase receptors 2 (receptors of VEGF, Ang-2, and Ang-1) with CD31, indicating the potential crosstalk between the neurons and ECs (Fig. 7e) .
Blocking JAK2/STAT3 signaling attenuates the Sals-induced post-stroke angiogenesis, neurological recovery, and modulation of proangiogenic factors To further confirm the proangiogenic role of JAK2/STAT3 signaling pathway activated by Sals, a JAK2 inhibitor AG490 was administrated to the stroke mice. No difference was observed in the microvessel density among the dMCAO, dMCAO + AG490, and Sals (30 mg/kg, i.p.) + AG490 groups at day 14, suggesting that Sals-induced increase in microvessel density was potentially inhibited by AG490 ( Figure S3a and b) . Importantly, the functional recovery induced by Sals was also significantly diminished by AG490 at day 14 and 28 ( Figure S3c and d ). Next, we tested the influences of JAK2/STAT3 blockage on the Sals-induced modulation of VEGF, Ang-1, and Ang-2. Administration of AG490 dramatically suppressed the induction of VEGF and Ang-1 caused by Sals, while restored the expression of Ang-2 that was reduced by Sals treatment (Figure S3e and f) . Taken together, these observations indicated that JAK2/ STAT3 signaling pathway activated by Sals mediated poststroke angiogenesis process via regulating the production of proangiogenic factors.
Discussion
Our data have demonstrated for the first time that Sals treatment significantly enhances angiogenesis in ischemic brain through JAK2/STAT3 signaling pathway and promotes pericytes and astrocytes coverage around microvessels to stabilize vessel walls, resulting in significant improvement of post-stroke neurological recovery. Moreover, our study has revealed that Sals modulate the production of VEGF, Ang-1, and Ang-2, which may participate in the formation, remodeling, and maturation of the vasculature, in a JAK2/STAT3 pathway-dependent manner.
Angiogenesis is essential for neurovascular remodeling as it improves blood flow and metabolism in the ischemic boundary in the later stages of stroke (Beck and Plate 2009 ).
Stroke patients with sufficient blood flow always experience favorable outcomes (Krupinski et al. 1994; Liu et al. 2014a) . Therefore, finding strategies to promote angiogenesis appears promising to yield potential therapeutic targets for ischemic stroke. However, many effective drugs tested in the laboratory fail to translate to the clinical application for some reasons, at least one of the reasons is that they must be given immediately after or within the early stage after the onset of stroke. In this study, we have demonstrated that Sals treatment of stroke starting from 24 h after dMCAO, similar to the clinical treatment strategy, significantly improves functional recovery. Although direct relationship between newly formed vessels and functional outcomes is unclear, the beneficial effects of angiogenesis on functional outcomes have been documented for decades (Chen et al. 2007; Wang et al. 2014) . This supports our results that systemic administration of Sals for 14 continuous days significantly enhanced angiogenesis and EC proliferation in ischemic brain, contributing to the functional recovery improvement. It should be noted that post-stroke neurological recovery is a complex procedure that is regulated by multiple factors. Thus, further study is needed to unveil other underlying mechanisms.
Newly generated vessels tend to be permeable prominently during acute stages of vascular development (Thurston et al. 2000; Greenberg and Jin 2005) . This transient increased vascular leakage has been used to identify the formation of new blood vessels (Jiang et al. 2005; Zhang and Chopp 2009) . Interestingly, the extravasation of Evans blue was significantly increased at day 7, while it declined from day 14 to 28, suggesting a robust formation of immature vessels at day 7 followed by stabilization of new vessels starting from day 14. Our finding is in agreement with the temporal course of post-ischemic angiogenesis reported in previous studies (Beck and Plate 2009; Zhang and Chopp 2009; Shlosberg et al. 2010) . Furthermore, in our experiments, Sals-treated mice showed more extravasation at day 7, indicating that microvessel density was increased significantly after Sals treatment. However, further study is needed to evaluate the effects of Sals on cerebral blood flow after stroke. Our data have suggested that Sals might markedly enhance angiogenesis without increasing vascular permeability in the brain ischemic boundary, consistent with the previous reports of the proangiogenic effects of Sals on myocardial infarction (Guo et al. 2014; Li et al. 2014) .
Structural remodeling is indispensable for the late phase angiogenesis, which is regulated via intimate connection and coordination of neurovascular components such as ECs, pericytes, and astrocytes (Janzer and Raff 1987; Ramsauer et al. 2002; Armulik et al. 2005) . During vessel maturation, pericytes proliferated is recruited, and the cell bodies contact with ECs directly, while astrocytes lie abluminally, through their endfeet interaction with ECs. Coverage of pericytes and astrocytic endfeet inversely correlates with the microvascular permeability (Quaegebeur et al. 2011; Vallon et al. 2014 ). Our present study has shown that Sals treatment promotes both astrocytic endfeet and pericytes coverage of microvessels. Although the role of astrogliosis in cerebral ischemia is controversial, beneficial effects of reactive astrocytes during neurovascular remodeling process have been unveiled (Choudhury and Ding 2016) , which strongly support the protective effect of Sals on neurovascular remodeling against stroke (Hayakawa et al. 2010) .
VEGF, the most critical driver of vascular formation, is upregulated at the early stage of angiogenesis, promoting cerebral-vessel sprouting to form immature vessels. Ang-1 leads to maturation of the initial vessels and Ang-2 is a destabilizing signal molecule that reverts vessels to a more plastic state (Zhang and Chopp 2009) . These factors must act in perfect harmony to form functional vessels. Our study has revealed that the expression of VEGF is significantly elevated by Sals at day 3, persisting up to day 14. However, the modulation of Ang-1 and Ang-2 by Sals was not observed until day 7. Indeed, the differential time frames may explain our results of Evans blue extravasation. Our results are in line with previous studies that VEGF and Angs act in a complementary and coordinated pattern (Zhang et al. 2002; Zhu et al. 2005) . In addition, we have demonstrated that VEGF, Ang-1, and Ang-2 are mainly produced in neurons but not ECs or astrocytes after Sals treatment, also consistent with previous studies (Kovacs et al. 1996; Zheng et al. 2011) . However, the expression of their receptors can be found in ECs, implicating that the proangiogenic effects of Sals may be dependent on the communication between neurons and ECs. The JAK2/STAT3 signaling pathway is involved in cell proliferation, cell-cycle progression, and angiogenesis, and it is associated with antiphospholipid antibodies-mediated inhibition of endometrial angiogenesis and leptin-induced neovascularization in diabetic retinopathy (Darnell et al. 1994; Suganami et al. 2004; D'Ippolito et al. 2012; Raible et al. 2014) . Especially, increasing evidence has shown that the JAK2/STAT3 signaling pathway plays a primary role in stroke induced angiogenesis (Sakata et al. 2012; Hoffmann et al. 2015) . Thus, we investigated the role of the JAK2/ STAT3 signaling pathway in Sals-induced post-stroke angiogenesis. Our study has demonstrated that the phosphorylation of JAK2 and STAT3 is enhanced significantly after Sals treatment, and the JAK2 inhibitor completely abolishes the beneficial effects of Sals on microvessel density and functional recovery. The modulation of proangiogenic factors by Sals is also reversed by the blockage of JAK2/STAT3 pathway. In line with our results, STAT3 has been reported to induce VEGF expression in cardiac myocytes, mesenchymal stem cells, tumor cells, and cerebral endothelial cells (Funamoto et al. 2000; Wang et al. 2007; Hansen et al. 2015; Hoffmann et al. 2015) . However, there is no direct evidence showing the association between STAT3 and Angs. Accumulating evidence has shown that HIF and matrix metalloproteinase, induced by JAK2/STAT3 signaling, participates in angiogenesis. And interleukin 6 and interleukin 10 can act as upstream mediators of STAT3 (Huynh et al. 2017) . However, it remains unclear whether the underlying mechanisms of Sals on angiogenesis are related to these factors. And how Sals affect JAK2/STAT3 signaling regulations was not investigated. It will be a focus of our future study. Taken together, our findings suggested that the proangiogenic effects of Sals might be mediated by the JAK2/STAT3 signaling pathway.
To the best of our knowledge, this study is the first in vivo mechanistic study demonstrating that post-stroke treatment of Sals enhances angiogenesis and improves long-term functional recovery through the JAK2/STAT3 signaling pathway. Our findings lead to a better understanding of the beneficial effects of Sals against ischemic stroke, and may provide an alternative strategy for potential clinical trials. 81401098). The authors declare that they have no conflict of interest.
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